10-K: Sonendo, Inc. Reports 2023 Financial Results and Strategic Divestiture

Sonendo, Inc. reports a net loss of $60.9 million on revenue of $43.9 million for 2023, while divesting its software segment to focus on its core medical technology business.

Summary

• Sonendo, Inc., a medical technology company, reported a net loss of $60.9 million for the year ended December 31, 2023, compared to a net loss of $57.1 million in 2022.
• The company's revenue for 2023 was $43.9 million, an increase from $41.7 million in 2022.
• As of December 31, 2023, Sonendo had an accumulated deficit of $430.0 million.
• The company divested its software segment in March 2024 for approximately $16.0 million, receiving $15.0 million upfront and the balance due in approximately 12 months.
• Sonendo made a $15.0 million principal repayment on its term loan in connection with the software divestiture and agreed to make monthly amortization payments of $0.9 million commencing April 30, 2024.
• The company had an installed base of approximately 1,134 GentleWave Systems as of December 31, 2023, with over 1.3 million patient procedures performed since commercialization.
• The company launched the second generation of its CleanFlow PI in 2023, which has an optimized design and enhanced matrix system.
• The company discontinued the sale of its legacy GentleWave Gen3 system in 2023, focusing on the G4 console which is assembled in-house.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is revenue growth and strategic action with the divestiture, the increasing net loss, potential delisting, and need for additional funding create a negative outlook. The company faces significant challenges and risks.

Positives

• The company's revenue increased by 5% year-over-year.
• The launch of the CleanFlow G2 PI simplifies the root canal treatment process for clinicians.
• The company has treated over 1.3 million patients with the GentleWave Procedure.
• The company's in-house assembly of the G4 console has improved gross margin and operating leverage.

Negatives

• The company's net loss increased to $60.9 million in 2023 from $57.1 million in 2022.
• The company has an accumulated deficit of $430.0 million.
• The company's common stock was suspended from trading on the NYSE and may be delisted.
• The company is dependent on the success of its GentleWave System and related PIs for revenue.

Risks

• The company is an early-stage company with a history of significant net losses and expects to continue to incur operating losses.
• The company's common stock has been suspended from trading on the NYSE and may be delisted.
• The company's revenue is primarily generated from sales of the GentleWave Console and PIs, making it highly dependent on their success.
• The company's future operating results may be difficult to predict and could fall below expectations.
• The company's credit agreement contains operating and financial covenants that restrict its flexibility.
• The company needs additional funding to finance its operations and may not be able to raise capital when needed.
• The commercial success of the GentleWave System depends on market acceptance by dental practitioners.
• The company may not be able to obtain or maintain adequate levels of third-party coverage and reimbursement.
• The company may not be able to compete successfully or develop new products on a timely basis.
• The company has limited experience manufacturing its products in large-scale commercial quantities and depends on third-party suppliers.
• The company's internal computer systems may fail or suffer security breaches.
• The sizes of the addressable markets for the GentleWave System have not been established with precision.
• The company may incur substantial liabilities from product liability lawsuits.
• The company's ability to utilize net operating loss carryforwards may be limited.
• The company is highly dependent on its senior management team.
• The market price of the company's common stock may be volatile and an active trading market may not develop.
• The company maintains cash deposits in excess of federally insured limits, which could be at risk due to bank failures.

Future Outlook

The company expects to continue to incur net losses for the next several years and will require additional financing to fund its operations and planned growth. The company plans to continue to make investments in its sales and marketing organization, research and development, regulatory affairs and clinical studies.

Industry Context

The company operates in the competitive medical device industry, facing competition from manufacturers and suppliers of devices, instruments and other supplies used in connection with conventional treatments for root canals. The company is focused on establishing the GentleWave Procedure as the standard of care for root canal therapy.

Comparison to Industry Standards

• The company competes with larger, more established companies like Dentsply Sirona, Envista, and Henry Schein, which have greater resources and name recognition.
• The company's technology represents an innovative approach to root canal treatment, competing directly against conventional methods.
• The company's success depends on overcoming established treatment patterns and educating patients and clinicians about the benefits of the GentleWave System.
• The company's recurring revenue model, based on sales of single-use PIs, is a common strategy in the medical device industry.

Stakeholder Impact

• Shareholders face the risk of stock price volatility and potential delisting from the NYSE.
• Employees may be affected by potential restructuring and cost-cutting measures.
• Customers (dental practitioners) may benefit from the improved CleanFlow G2 PI and the company's focus on its core technology.
• Creditors (lenders) are impacted by the company's debt repayment and covenant modifications.

Next Steps

• The company plans to continue to invest in its sales and marketing organization.
• The company plans to continue to invest in research and development, regulatory affairs and clinical studies.
• The company plans to pursue marketing authorizations and similar certifications to enable marketing and engage in other market access initiatives over time in attractive international regions.

Key Dates

Keywords

GentleWave System, root canal therapy, medical technology, dental, endodontics, procedure instruments, software divestiture, financial results, net loss, revenue